This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Forget Market Volatility With These Dividend Growth Stocks
by Sweta Killa
Zeroing in on companies that not only offer dividends but also consistently increase their payouts seems like a good idea.
Thermo Fisher (TMO) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Thermo Fisher (TMO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Investors' confidence is high in the Accuray (ARAY) stock, thanks to its solid prospects.
Here's Why You Should Retain AMN Healthcare (AMN) Stock Now
by Zacks Equity Research
AMN Healthcare (AMN) continues to gain traction from its wide range of services, and Healthcare MSP. Intense competition remains a woe.
Allscripts Completes Sale of EPSi Business to Strata
by Zacks Equity Research
Allscripts (MDRX) completes the sale of its EPSi business to Strata. Notably, the combination of two companies can reduce cost associated with healthcare.
Boston Scientific Gets a Boost From MedSurg Arm Amid Coronavirus
by Zacks Equity Research
Within Endoscopy, Boston Scientific (BSX) believes that business recovery started since June.
Thermo Fisher Scientific (TMO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher (TMO) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
In the third quarter, Thermo Fisher (TMO) invests more than $140 million to increase the production of its laboratory plastic consumables.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Nevro (NVRO) continues to gain traction from its flagship platform, Senza, and R&D capabilities. However, stiff competition remains a woe.
Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed the most recent trading day at $467.53, moving +0.17% from the previous trading session.
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher
Abbott's New Antibody Test Gets FDA's EUA, Test Suite Expands
by Zacks Equity Research
Abbott's (ABT) latest antibody test is expected to give a clearer picture of the rate of recovery post coronavirus infection.
Here's Why You Should Add AngioDynamics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high in AngioDynamics (ANGO) stock, thanks to solid prospects.
Here's Why You Should Hold on to Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
What's in Store for Intuitive Surgical's (ISRG) Q3 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter earnings are likely to reflect weaker-than-expected performance at Instruments & Accessories segment.
Is Thermo Fisher Scientific (TMO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Bruker Rides on Nano and MALDI Launches Despite Margin Debacle
by Zacks Equity Research
Bruker (BRKR) has several Bruker NANO products that are being assembled and tested in Malaysia.
Abbott's Data From Interim Clinical Study of ID NOW Positive
by Zacks Equity Research
Abbott's (ABT) recent data from an interim clinical study on its ID NOW COVID-19 rapid test reflects the test's capacity to deliver effective, consistent and reliable performance.
Veeva Develops 2 Applications on Veeva Clinical Network (Revised)
by Zacks Equity Research
This should boost Veeva's (VEEV) portfolio of cloud-based offerings for the life sciences industry.
Bio-Rad (BIO) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Bio-Rad (BIO) is optimistic about maintaining robust testing portfolio along with strength in its Life Sciences business.
Booming Gene Editing Market to Pep Up These 5 Biotech Stocks
by Zacks Equity Research
Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.
NuVasive's (NUVA) MaXcess Retractor Study Results Positive
by Zacks Equity Research
NuVasive's (NUVA) MaXcess retractor's ability to perform lateral surgery in various approaches, including prone position, is validated by favorable study outcome.
3 Large-Cap MedTech Growth Stocks to Buy Amid the Pandemic
by Sriparna Ghosal
Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.
Ecolab Introduces New Automated Precision Dispensing System
by Zacks Equity Research
Ecolab's (ECL) newly launched Precision Dispensing System for Membranes can drive productivity and boost worker safety.
Pacific Biosciences Unveils Sequel IIe for HiFi Sequencing
by Zacks Equity Research
Pacific Biosciences' (PACB) recently-launched Sequel IIe System is powered by its SMRT technology.